HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use FENTANYL CITRATE INJECTION safely and effectively. See full prescribing information for FENTANYL CITRATE INJECTION.

FENTANYL CITRATE injection, for intravenous or intramuscular use, CII Initial ILS Approval: 1968

- WARNING: RISK OF ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; CYTOCHROME P450 3A4 INTERACTION: and BISKS FROM CONCOMITANT US WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
- See full prescribing information for complete boxed warning. Fentanyl Citrate Injection exposes users to risks of addiction abuse, and misuse, which can lead to overdose and death. As patient's risk before prescribing and monitor regularly for these
- haviors and conditions (5.1) Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (5.2)
- Concomitant use with CYP3A4 inhibitors (or discontinuation o CYP3A4 inducers) can result in a fatal overdose of fentanyl. (5.3, 7, 12.3)
- Concomitant use of opioids with benzodiazepines or other centra nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (5.4, 7)

- INDICATIONS AND USAGE

- Fentanyl Citrate Injection is indicated for: analgesic action of short duration during the anesthetic periods, premedi
- cation, induction and maintenance, and in the immediate postoperative od (recovery room) as the need arises. use as an opioid analgesic supplement in general or regional anesthesia
- administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia
- use as an anesthetic agent with oxygen in selected high risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.

----- DOSAGE AND ADMINISTRATION -----

- Fentanyl Citrate Injection should be administered only by persons specifi-cally trained in the use of intravenous anesthetics and management of the iratory effects of potent opioids Ensure that an opioid antagonist, resuscitative and intubation equipment,
- and oxygen are readily available (2.1).
 Individualize dosing based on the factors such as age, body weight,
- physical status, underlying pathological condition, use of other drugs type of anesthesia to be used, and the surgical procedure involved. (2.1)

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING BISK OF ADDICTION ABUSE AND MISUSE LIFE THREATENING RESPIRATORY DEPRESSION; CYTOCHROME P450 3A4 INTERACTION: and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS INDICATIONS AND USAGE

- 2 DOSAGE AND ADMINISTRATION
- Important Dosage and Administration Instructions
- 2.2 Dosage
- 3 DOSAGE FORMS AND STRENGTHS

Rx only

451610D /Revised: August 2023

Fentanyl Citrate

Injection, USP

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- Addiction, Abuse, and Misuse Life-Threatening Respiratory Depression
- Risks of Concomitant Use or Discontinuation of Cytochrome 5.3 P450 3A4 Inhibitors and Inducers
- 5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS
- Risks of Muscle Rigidity and Skeletal Muscle Movement
- Severe Cardiovascular Depression
- Serotonin Syndrome with Concomitant Use of Serotonergic
- Adrenal Insufficiency
- 5.9 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors or Head Injury
- Risks of Use in Patients with Gastrointestinal Conditions 5 10
- Increased Risk of Seizures in Patients with Seizure Disorders
- 5.12 Risks of Driving and Operating Machinery 5.13 Risks due to Interaction with Neuroleptic Agents

FULL PRESCRIBING INFORMATION

WARNING: RISK OF ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION: CYTOCHROM P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction. Abuse. and Misuse

- Fentanyl Citrate Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing Fentanyl Citrate Injection, and monitor all patients regularly for the development o these behaviors and conditions [see Warnings and Precautions (5.1)] Life-Threatening Respiratory Depression
- eatening, or fatal respiratory depression may occu with use of Fentanyl Citrate Injection. Monitor for respiratory depres sion, especially during initiation of Fentanyl Citrate Injection of following a dose increase [see Warnings and Precautions (5.2)] Cytochrome P450 3A4 Interaction

The concomitant use of Fentanyl Citrate Injection with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reaction and may cause potentially fatal respiratory depression. In addition discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Monitor patients receiving Fentanyl Citrate Injection and any CYP3A4 nhibitor or inducer [see Warnings and Precautions (5.3), Drug Interactions (7), Clinical Pharmacology (12.3)].

- Initiate treatment in adults with 50 mcg to 100 mcg. (2.2)
- Initiate treatment in children 2 to 12 years of age, with a reduced dose as low as 2 mcg/kg to 3 mcg/kg. (2.2)

- DOSAGE FORMS AND STRENGTHS

Fentanyl Citrate Injection, equivalent to 50 mcg fentanyl base per mL. is a preservative-free solution, available in 1 mL, 2 mL, 5 mL, 20 mL, 50 mL single-dose glass vials. (3)

Hypersensitivity to fentanyl (4)

- <u>Risks of Skeletal Muscle Rigidity and Skeletal Muscle Movement</u>: Manage with neuromuscular blocking agent. See full prescribing information for more detail on managing these risks. (5.5)
- Severe Cardiovascular Depression: Monitor during dosage initiation and titration. (5.6)
- Serotonin Syndrome: Potentially life-threatening condition could result
- concomitant serotonergic drug administration. Discontinue Fentanyl Citrate Injection if serotonin syndrome is suspected. (5.7) • <u>Adrenal Insufficiency</u>: If diagnosed, treat with physiologic replacement of
- teroids and wean natient off of the opioid (5.8)
- Bisks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, or Head Injury: Monitor for sedation and respiratory depression. (5.9)

Most common serious adverse reactions were respiratory depression. apnea, rigidity, and bradycardia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

- DRUG INTERACTIONS

- Concomitant Use of CNS Depressants: May decrease pulmonary arterial pressure and may cause hypotension. See FPI for management instruc-tions. For post-operative pain, start with the lowest effective dosage and
- monitor for potentiation of CNS depressant effects (5.4.7) • Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Fentanyl Citrate Injection because they may reduce the analogsic
- effect of Fentanyl Citrate Injection or precipitate withdrawal symptoms. (7) - USE IN SPECIFIC POPULATIONS -

• Pregnancy: May cause fetal harm. (8.1)

- Lactation: Infants exposed to Fentanyl Citrate Injection through breast milk should be monitored for excess sedation and respiratory depression. (8.2)
- · Geriatric Patients: Titrate slowly and monitor for CNS and respiratory

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2023

- 6 ADVERSE REACTIONS
- 7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- Pregnancy Lactation
- Females and Males of Reproductive Potential
- Pediatric Use 84
- Geriatric Use
- Hepatic Impairment Renal Impairment

9 DRUG ABUSE AND DEPENDENCE

- Controlled Substance Abuse
- 9.3 Dependence
- 10 OVERDOSAGE

11 DESCRIPTION

- 12 CLINICAL PHARMACOLOGY
- Mechanism of Action Pharmacodynamics
- 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
- Carcinogenesis, Mutagenesis, Impairment of Fertility
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION

$\ensuremath{^*\text{Sections}}$ or subsections omitted from the full prescribing information are not listed.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alco may result in profound sedation, respiratory depression, coma, and death [see Warnings and Precautions (5.4), Drug Interactions (7 Reserve concomitant prescribing of Fentanyl Citrate Injectio

- and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate
- Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depres-
- sion and sedation

INDICATIONS AND USAGE

- Fentanyl Citrate Injection is indicated for:
- analgesic action of short duration during the anesthetic periods premedication, induction and maintenance, and in the immediate stoperative period (recovery room) as the need arises
- use as a narcotic analgesic supplement in general or regional anesthesia
- administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the
- maintenance of general and regional anesthesia. • use as an anesthetic agent with oxygen in selected high risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures

2 DOSAGE AND ADMINISTRATION

Monitor vital signs routinely.

from anesthesia

60 minutes prior to surgery.

High dose—20 mcg/kg to 50 mcg/kg

Adjunct to General Anesthesia See Dosage Range Charts below

For use in minor, but painful, surgical procedures

analgesia, may abolish some of the stress response.

xtended post-operative respiratory depression

Moderate Dose-2 mcg/kg to 20 mcg/kg

permit

Low Dose-2 mcg/kg

ential

ninor procedures

25 mcg to 100 mcg

of analgesia.

time is short

required.

As a General Anesthetic

orthopedic procedures.

DOSAGE FORMS AND STRENGTHS

20 mL, 50 mL single-dose glass vials.

WARNINGS AND PRECAUTIONS

Needle Usage

1 inch in length.

Single-Dose Vials

CONTRAINDICATIONS

5.1 Addiction, Abuse, and Misuse

Dependence (9)].

2.2 Dosage

2.1 Important Dosage and Administration Instructions entanyl Citrate Injection should be administered only by persons ment of the respiratory effects of potent opioids

equipment, and oxygen are readily available.

pecifically trained in the use of intravenous anesthetics and manage-

Ensure that an opioid antagonist, resuscitative and intubation

Individualize dosage based on factors such as age, body weight physical status, underlying pathological condition, use of othe

As with other potent opioids, the respiratory depressant effect o

fentanyl may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered

by the practitioner before ordering opioid analgesics during recover

If Fentanyl Citrate Injection is administered with a CNS depressan

become familiar with the properties of each drug particularly each

product's duration of action. In addition, when such a combination

is used, fluids and other countermeasures to manage hypotension

Inspect parenteral drug products visually for particulate matter and

Premedication in Adults 50 mcg to 100 mcg may be administered intramuscularly 30 to

Table 1: Dosage Range Chart

Total Dosage (expressed as fentanyl base)

May also provide some pain relief in the immediate postoperative period

Moderate Dose—2 mcg/kg to 20 mcg/kg For use in more major surgical procedures, in addition to adequate

Expect respiratory depression requiring artificial ventilation durin

anesthesia and careful observation of ventilation postoperatively is

For open heart surgery and certain more complicated neurosurgical and

orthopedic procedures where surgery is more prolonged, and the stress response to surgery would be detrimental to the well-being of the patient. In conjunction with nitrous oxide/oxygen has been shown to attenuate

the stress response as defined by increased levels of circulating growth hormone, catecholamine, ADH and prolactin.

Expect the need of postoperative ventilation and observation due to

Maintenance Dose (expressed as fentanyl base)

Low Dose-2 mcg/kg Additional dosages infrequently needed in these

Administer intravenously or intramuscularly as needed when movement

and/or changes in vital signs indicate surgical stress or lightening of

High Dose—20 mcg/kg to 50 mcg/kg Maintenance dosage Iranging from 25 mcg to one half the initial loading

dose] as needed based on vital signs indicative of stress and lightening

lividualize the dosage especially if the anticipated remaining operative

<u>Adjunct to Regional Anesthesia</u> 50 mcg to 100 mcg may be administered intramuscularly or slowly

ntravenously, over one to two minutes, when additional analgesia is

Postoperatively (recovery room) 50 mcg to 100 mcg may be administered intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may

hnique to attenuate the responses to surgical stress without

For Induction and Maintenance in Children 2 to 12 Years of Age A reduced dose as low as 2 mcg/kg to 3 mcg/kg is recommended

the use of additional anesthetic agents, doses of 50 mcg/kg to

In certain cases, doses up to 150 mcg/kg may be necessary to

produce this anesthetic effect. It has been used for open hear

surgery and certain other major surgical procedures in patients for whom protection of the myocardium from excess oxygen demand is

particularly indicated, and for certain complicated neurological and

Use caution when penetrating vial stopper with a needle exceeding

entanyl Citrate Injection, USP, equivalent to 50 mcg fentanyl base

• Hypersensitivity to fentanyl (e.g., anaphylaxis) [See Adverse Reactions (6)]

Fentanyl Citrate Injection contains fentanyl, a Schedule II controlled

substance. As an opioid, Fentanyl Citrate Injection exposes users

to the risks of addiction, abuse, and misuse [see Drug Abuse and

per mL, is a preservative-free solution, available in 1 mL, 2 mL, 5 mL,

Fentanyl Citrate Injection is contraindicated in patients with:

100 mcg/kg may be administered with oxygen and a muscle relax

be repeated in one to two hours as needed.

liscoloration prior to administration, whenever solution and container

should be available [see Warnings and Precautions (5.4)]

drugs, type of anesthesia to be used, and the surgical procedure

Opioids are sought by drug users and people with addiction disorders and are subject to criminal diversion. Consider these risks when nandling Fentanyl Citrate Injection. Strategies to reduce these risks include proper product storage and control practices for a C-II drug Contact local state professional licensing board or state cont substances authority for information on how to prevent and detect abuse or diversion of this product.

5.2 Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended espiratory depression, if not immediately recognized and treated may lead to respiratory arrest and death. Adequate facilities should be available for postoperative monitoring and ventilation of patients administered anesthetic doses of Fentanyl Citrate Injection. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression. Management of respiratory depression include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status /see Overdosage (10)1, Carbon dioxide (CO₂) retention from opioid induced respiratory depression can exacerbate the sedating effects of opioids.

To reduce the risk of respiratory depression, proper dosing and titration of Fentanyl Citrate Injection are essential. As with other poten opioids, the respiratory depressant effect of Fentanyl Citrate Injection may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia.

Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics can alter respiration by blocking inter costal nerves. Through other mechanisms [see Clinical Pharma (12.2) Fentanyl Citrate Injection can also alter respiration. Therefore when Fentanyl Citrate Injection is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients selected for these forms of anesthesia.

Patients with significant chronic obstructive pulmonary disease of cor pulmonale and those with a substantially decreased respiratory erve, hypoxia, hypercapnia, or pre-existing respiratory depress are at increased risk of decreased respiratory drive including appea even at recommended dosages of Fentanyl Citrate Injection. Elderly cachectic, or debilitated patients may have altered pharmacokinetics or altered clearance compared to younger, healthier patients resulting in greater risk for respiratory depression.

Monitor such patients closely including vital signs, particularly when initiating and titrating Fentanyl Citrate Injection and when Fentanyl Citrate Injection is given concomitantly with other drugs that depress respiration. To reduce the risk of respiratory depression, proper ing and titration of Fentanyl Citrate Injection are essential [see Dosage and Administration (2.1)1.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA consider decreasing the opioid dosage usin est practices for opioid taper [see Dosage and Administration (2.1)]

5.3 Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers

Concomitant use of Fentanyl Citrate Injection with a CYP3A4 inhibitor such as macrolide antibiotics (e.g., erythromycin), azole-antifunga agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) nay increase plasma concentrations of fentanyl and prolong opioid adverse reactions which may exacerbate respiratory depression [see Warnings and Precautions (5.2)], particularly when an inhibitor is added after a stable dose of Fentanyl Citrate Injection is achieved. ilarly, discontinuation of a CYP3A4 inducer, such as rifampir carbamazepine, and phenytoin, in Fentanyl Citrate Injection-treated patients may increase fentanyl plasma concentrations and prolong opioid adverse reactions. When using Fentanyl Citrate Injection with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in Fentanyl Citrate Injection-treated patients, monitor patients closely at frequent intervals and consider dosage reduction of Fentanyl Citrate Injection [see Dosage and Administration (2.1), Drug Interactions (7)].

Concomitant use of Fentanyl Citrate Injection with CYP3A4 inducers or discontinuation of a CYP3A4 inhibitor, could result in lower than expected fentanyl plasma concentrations and, decrease efficacy. When using Fentanyl Citrate Injection with CYP3A4 inducers, or continuation of a CYP3A4 inhibitor, monitor patients closely at frequent intervals and consider increasing the Fentanyl Citrate tion dosage [see Dosage and Administration (2.1), Drug Interactions (7)

5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants

When benzodiazepines or other CNS depressants are used with Fentanyl Citrate Injection, pulmonary arterial pressure may be decreased. This fact should be considered by those who conduct diagnostic and surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient. When high dose or anesthetic dosages of Fentanyl Citrate Injection are employed, even relatively small dosages of diazepam may cause cardiovascular depression.

When Fentanyl Citrate Injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blo pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Fentanyl Citrate Injection with benzodiazepines or other CNS depressants (e.g., nonbenzodiazepine edatives/hypnotics, anxiolytics, tranquilizers, muscle relaxa general anesthetics, antipsychotics, other opioids, alcohol). If the decision is made to manage postoperative pain with Fentanyl Citrate Injection concomitantly with a benzodiazepine or other CNS depressant, start dosing with the lowest effective dosage and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available [see Drug Interactions (7)

5.5 Risks of Muscle Rigidity and Skeletal Muscle Movement

Fentanyl Citrate Injection may cause muscle rigidity, particularly involving the muscles of respiration. The incidence and severity of muscle rigidity is dose related. These effects are related to the dose and speed of injection. Skeletal muscle rigidity also has been reported to occur or recur infrequently in the extended postoperative period usually following high dose administration. In addition, skeletal muscle movements of various groups in the extremities, neck, and external eye have been reported during induction of anesthesia with Fentanyl Citrate Injection: these reported movements have on rare occasions been strong enough to pose patient management problems.

These effects are related to the dose and speed of injection and its idence can be reduced by: 1) administration of up to 1/4 of the full paralyzing dose of a non-depolarizing neuromuscular blocking agent just prior to administration of Fentanyl Citrate Injection administration of a full paralyzing dose of a neuromuscular blocking igent following loss of eyelash reflex when Fentanyl Citrate Injection s used in anesthetic doses titrated by slow intravenous infusion: o 3) simultaneous administration of Fentanyl Citrate Injection and a full paralyzing dose of a neuromuscular blocking agent when Fentanyl Citrate Injection is used in rapidly administered anesthetic dosage he neuromuscular blocking agent used should be compatible with the patient's cardiovascular status.

5.6 Severe Cardiovascular Depression

Fentanyl Citrate Injection may cause severe bradvcardia. severe ypotension, and syncope. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see Drug Interactions (7)]. In patients with circulatory shock, Fentanyl Citrate Injection may cause vasodilation that can further reduce cardiac output and blood pressure. Monitor these patients for signs of hypotension after initiating or titrating the dosage of Fentanyl Citrate Injection.

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs 5.7 Cases of serotonin syndrome, a potentially life-threatening condi-tion, have been reported during concomitant use of fentanyl with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricvclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAO inhibitors both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7)]. This may occur within the recommended dosage range.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., achycardia, labile blood pressure, hyperthermia), neuromuscula aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days of concomitant use, but may occur later than that. Discontinue Fentanyl Citrate Injection if serotonin syndrome is suspected.

5.8 Adrenal Insufficiency

Cases of adrenal insufficiency have been reported with opioid use. more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs icluding nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure. If adrenal insufficiency is suspected, confirm he diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

5.9 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, or Head Injury In patients who may be susceptible to the intracranial effects of CO₂

retention (e.g., those with evidence of increased intracranial pressure or brain tumors). Fentanyl Citrate Injection may reduce respiratory drive. and the resultant CO₂ retention can further increase intracranial pressure. Monitor such patients for signs of increasing intracranial pressure.

- 5.10 Risks of Use in Patients with Gastrointestinal Conditions Fentanyl may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms.
- 5.11 Increased Risk of Seizures in Patients with Seizure Disorders Fentanyl may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in ther clinical setting associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during Fentanyl Citrate Injection therapy.
- 5.12 Risks of Driving and Operating Machinery Fentanyl Citrate Injection may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving

a car or operating machinery after Fentanyl Citrate Injection administration.

5.13 Risks due to Interaction with Neuroleptic Agents Many neuroleptic agents have been associated with QT prolongatio torsades de pointes, and cardiac arrest. Administer neuroleptic agents vith extreme caution in the presence of risk factors for develop ment of prolonged QT syndrome and torsades de pointes, such as:) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, including baseline prolonged QT interval. treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance.

Elevated blood pressure, with and without pre-existing hyperten sion, has been reported following administration of Fentanyl Citrate Injection combined with a neuroleptic. This might be due to unexplained alterations in sympathetic activity following large dose however, it is also frequently attributed to anesthetic and surgical timulation during light anesthesia.

ECG monitoring is indicated when a neuroleptic agent is used in conjunction with Fentanyl Citrate Injection as an anesthetic premedication, for the induction of anesthesia, or as an adjunct in the maintenance of general or regional anesthesia.

When Fentanyl Citrate Injection is used with a neuroleptic and an EEG is used for postoperative monitoring, the EEG pattern may return to ormal slowly

ADVERSE REACTIONS

- The following serious adverse reactions are described, or described in greater detail, in other sections. Addiction, Abuse, and Misuse (see Warnings and Precautions
- Life-Threatening Respiratory Depression [see Warnings and Precautions (5 2)1
- Interactions with Benzodiazepines and Other CNS Depressants [see Warnings and Precautions (5.4)] Severe Cardiovascular Depression [see Warnings and Precautions
- Serotonin Syndrome [see Warnings and Precautions (5.7)]
 Gastrointestinal Adverse Reactions [see Warnings and
- Precautions (5 10)1 Seizures [see Warnings and Precautions (5.11)]

The following adverse reactions associated with the use of fentanyl were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their requency or establish a causal relationship to drug exposure

As with other opioid agonists, the most common serious adverse eactions reported to occur with fentanyl are respiratory depression, appeal rigidity and bradycardia; if these remain untreated, respiratory arrest, circulatory depression or cardiac arrest could occur. Other adverse reactions that have been reported are hypertension ypotension, dizziness, blurred vision, nausea, emesis, laryngo spasm, diaphoresis, serotonin syndrome, adrenal insufficiency, and anaphvlaxis.

It has been reported that secondary rebound respiratory depression may occasionally occur postoperatively. When a tranquilizer is used with Fentanyl Citrate Injection, the following adverse reactions can occur: chills and/or shivering, restlessness and postoperative hallucinatory episodes (sometimes associated with transient periods of mental depression); extrapyramidal symptoms (dystonia, akathisia and oculogyric crisis) have been observed up to 24 hours postoneratively. When they occur, extrapyramidal symptoms can usually be controlled with anti-parkinson agents Postoperative drowsiness is also frequently reported following the use of neuroleptics with fentanyl citrate

Cases of cardiac dysrhythmias, cardiac arrest, and death have been reported following the use of fentanyl citrate with a neuroleptic agent.

Serotonin syndrome: Cases of serotonin syndrome, a potentially ning condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month

Anaphylaxis: Anaphylaxis has been reported with ingredients ontained in Fentanyl Citrate Injection

Androgen deficiency: Cases of androgen deficiency have occurred with chronic use of opioids [see Clinical Pharmacology (12.2)].

DRUG INTERACTIONS Table 2 includes clinically significant drug interactions with Fentanyl Citrate Injection

Table 2: Clinically Significant Drug Interactions with

Fentanyl Citrate Injection						
Inhibitors of CYP3A4						
Clinical Impact:	The concomitant use of Fentanyl Citrate Injection and CYP3A4 inhibitors can increase the plasma concentration of fentanyl, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of Fentanyl Citrate Injection is achieved [see Warnings and Precautions (5.3)].					
	After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the fentanyl plasma concentration will decrease [see Clinical Pharmacology (12.3)], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to fentanyl.					
Intervention:	If concomitant use is necessary, consider dosage reduction of Fentanyl Citrate Injection until stable drug effects are achieved <i>[see Dosage and Administration (</i> (2.1)). Monitor patients for respiratory depression and sedation at frequent intervals.					
	If a CYP3A4 inhibitor is discontinued, consider increasing the Fentanyl Citrate Injection dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.					
Examples:	Macrolide antibiotics (e.g., erythromycin), azole- antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), grapefruit juice					
CYP3A4 Inducers						
Clinical Impact:	The concomitant use of Fentanyl Citrate Injection and CYP3A4 inducers can decrease the plasma concentration of fentanyl [see Clinical Pharmacology (12.3)], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to fentanyl [see Warnings and Precautions (5.3)].					
	After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase (see <i>Clinical Pharmacology (12.3)</i> , which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.					

Intervention: If concomitant use is necessary, consider increasing the entanyl Citrate Injection dosage until stable drug effect are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Fentany Citrate Injection dosage reduction and monitor for signs of respiratory depression Rifampin, carbamazepine, phenytoin Examples:

Table 2: Clinically Significant Drug Interactions with Fentanyl Citrate Injection (Continued)

Fentanyl Citrate Injection (Continued)						
Benzodiazepines and Other Central Nervous System (CNS) Depressants						
Clinical Impact:	The concomitant use of Fentanyl Citrate Injection with CNS depressants my result in decreased pulmonary artery pressure and may cause hypotension. Even small dosages of diazepam may cause cardiovascular depression when added to high dose or anesthetic dosages of Fentanyl Citrate Injection. As postoperative analgesia, concomitant use of Fentanyl Citrate Injection can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.					
Intervention:	As postoperative analgesia, start with a lower dose of Fentanyl Citrate Injection and monitor patients for signs of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available [see Warnings and Precautions (5.4)].					
Examples:	Benzodiazepines and other sedatives/hypnotics, anxiolytics, barbiturates, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.					
Serotonergic D						
Clinical Impact:	The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings and Precautions (5.7)].					
Intervention:	If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Fentanyl Citrate Injection if serotonin syndrome is suspected.					
Examples:	Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).					
Monoamine Oxi						
Clinical Impact:	MAOI interactions with opioids may manifest as serotonin syndrome [see Warnings and Precautions (5.7)] or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2)]					
Intervention:	The use of Fentanyl Citrate Injection is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.					
Examples: Mixed Agonist//	Phenelzine, tranylcypromine, linezolid Antagonist and Partial Agonist Opioid Analgesics					
Clinical Impact:	May reduce the analgesic effect of Fentanyl Citrate					
omiliou impuot.	Injection and/or precipitate withdrawal symptoms.					
Intervention:	Avoid concomitant use.					
Examples:	Butorphanol, nalbuphine, pentazocine, buprenorphine.					
Muscle Relaxar						
Clinical Impact: Intervention:	Fentanyl may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Monitor patients for signs of respiratory depression that					
	may be greater than otherwise expected and decrease the dosage of Fentanyl Citrate Injection and/or the muscle relaxant as necessary.					
Diuretics						
Clinical Impact: Intervention:	Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor patients for signs of diminished diuresis and/or					
Anticholinergic	effects on blood pressure and increase the dosage of the diuretic as needed. Drugs					
Clinical Impact:	The concomitant use of anticholinergic drugs may					
Intervention:	increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor patients for signs of urinary retention or reduced					
	gastric motility when Fentanyl Citrate Injection is used concomitantly with anticholinergic drugs.					
Neuroleptics	Elevated block and a set					
Clinical Impact:	Elevated blood pressure, with and without pre-existing hypertension, has been reported following administration of Fentanyl Citrate Injection combined with a neuroleptic [see Warnings and Precautions (5.13)].					
Intervention:	ECG monitoring is indicated when a neuroleptic agent is used in conjunction with Fentanyl Citrate Injection as an anesthetic premedication, for the induction of anesthesia, or as an adjunct in the maintenance of general or regional anesthesia.					
Nitrous oxide	-					
Clinical Impact:	Nitrous oxide has been reported to produce cardiovascular depression when given with higher doses of Fentanyl Citrate Injection.					
Intervention:	Monitor patients for signs of cardiovascular depression that may be greater than otherwise expected.					
3 USE IN SPECIFIC POPULATIONS 3.1 Pregnancy						
Risk Summ						
Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. Available data with Fentanyl Citrate Injection in pregnant women are insufficient to inform a drug- escapithd rick for majora brieth defacte and miscarcinga. In apingal						
associated risk for major birth defects and miscarriage. In animal						

associated risk for major birth defects and miscarriage. In animal

reproduction studies, fentanyl administration to pregnant rats during progenesis was embryocidal at doses within the range of the nan recommended dosing. No evidence of malformations was noted in animal studies completed to date [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a ackground risk of birth defect, loss, or other adverse outcomes. the U.S. general population, the estimated background risk of major irth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting diarrhea and failure to gain weight. The onset, duration, and severit of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly

Labor or Delivery There are insufficient data to support the use of fentanyl in labor or delivery. Therefore, such use is not recommended. Opioi cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory lepression in the neonate. Fentanyl Citrate Injection is not record mended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including Fentanyl Citrate Injection, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.

Animal Data

Fentanyl has been shown to be embryocidal in pregnant rats at doses of 30 mcg/kg intravenously (0.05 times the human dose of 100 mcg/kg on a mg/m² basis) and 160 mcg/kg subcutaneously (0.26 time the human dose of 100 mcg/kg on a mg/m² basis). There was no evidence of teratogenicity reported.

No evidence of malformations or adverse effects on the fetus was reported in a published study in which pregnant rats were adminis-tered fentanyl continuously via subcutaneously implanted osmotic minipumps at doses of 10, 100, or 500 mcg/kg/day starting 2-weeks prior to breeding and throughout pregnancy. The high dose was approximately 0.81 times the human dose of 100 mcg/kg on a mg/m²

8.2 Lactation

Risk Summary Fentanyl is present in breast milk. One published lactation study reports a relative infant dose of fentanyl of 0.38%. However, there is insufficient information to determine the effects of fentanyl on the breastfed infant and the effects of fentanyl on milk production he developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Fentanyl Citrate njection and any potential adverse effects on the breastfed infant Fentanyl Citrate Injection or from the underlying maternal condition.

Clinical Considerations Anitor infants exposed to fentanyl through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid nalgesic is stopped, or when breast-feeding is stopped.

8.3 Females and Males of Reproductive Potential

Chronic use of opioids may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions (6), Clinical harmacology (12.2), Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and efficacy of Fentanyl Citrate Injection in pediatric patients under two years of age has not been established.

Rare cases of unexplained clinically significant methemoglobinemia have been reported in premature neonates undergoing emergency anesthesia and surgery which included combined use of fentanyl ancuronium and atropine. A direct cause and effect relationsh between the combined use of these drugs and the reported cases o methemoglobinemia has not been established.

8.5 Geriatric Use

Elderly patients (aged 65 years or older) may have increased sensitivity to fentanyl. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Besniratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were admin istered to patients who were not opioid-tolerant or when opioids were o-administered with other agents that depress respiration. Titrate the dosage of Fentanyl Citrate Injection slowly in geniatric patients and nonitor closely for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.2)]

Fentanyl is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Hepatic Impairment

Fentanyl Citrate Injection should be administered with caution to patients with liver dysfunction because of the extensive hepatic metabolism. Reduce the dosage as needed and monitor closely for signs of respiratory depression, sedation, and hypotension

8.7 Renal Impairment

Fentanyl Citrate Injection should be administered with caution to patients with kidney dysfunction because of the renal excretion of Fentanyl Citrate Injection and its metabolites. Reduce the dosage as needed and monitor closely for signs of respiratory depression, sedation, and hypotension

9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance

Fentanyl Citrate Injection contains fentanyl, a Schedule II controlled drug substance.

9.2 Abuse

Fentanyl Citrate Injection contains fentanyl, a substance with a high potential for abuse similar to other opioids including hydrocodone phone, methadone, morphine, oxycodone, oxymorp and tapentadol. Fentanyl Citrate Injection can be abused and is ect to misuse, addiction, and criminal diversion [see Warnings and Precautions (5.1)]

Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.

Drug addiction is a cluster of behavioral. cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use. persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased lerance, and sometimes a physical withdrawal

Fentanyl Citrate Injection, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keepin of prescribing information, including quantity, frequency, and renewa requests, as required by state and federal law, is strongly advised.

Risks Specific to Abuse of Fentanyl Citrate Injection Abuse of Fentanyl Citrate Injection poses a risk of overdose and death. The risk is increased with concurrent use of Fentanyl Citrate Injection with alcohol and other central nervous system depressants.

Parenteral drug abuse is commonly associated with transmission of ectious diseases such as hepatitis and HIV.

9.3 Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawa also may be precipitated through the administration of drugs with opioid antagonist activity (e.g. naloxone nalmetene) mixed agonist antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine) or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.

10 OVERDOSAGE

<u>Clinical Presentation</u> Acute overdose with Fentanyl Citrate Injection can be manifested by respiratory depression, somnolence progressing to stupor or coma skeletal muscle flaccidity, cold and clammy skin, constricted pupils and, in some cases, pulmonary edema, bradycardia, hypotension partial or complete airway obstruction, atypical snoring, and death Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see Clinical Pharmacology (12.2)]

Treatment of Overdose


In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, f needed. Employ other supportive measures (including oxyg and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. The opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to fentaryl overdose, administer an opioid antagonist. Opioid antagonists should not be administered in the absence of clinically significant respiratory or ulatory depression secondary to opioid overdose. Because the duration of opioid reversal is expected to be less than the duration of action of fentanyl in Fentanyl Citrate Injection, carefully monitor the patient until spontaneous respiration is reliably re-established If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.

DESCRIPTION

11

Fentanyl Citrate Injection is an opioid agonist, available as a sterile. non-pyrogenic solution containing fentanyl citrate as the active pharmaceutical ingredient, for intravenous or inframuscular administration. Fentanyl citrate is chemically identified as N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1) with the following structural formula



 $C_{22}H_{28}N_2O \cdot C_6H_8O_7$ Molecular Weight is 528.59

Each mL contains fentanyl citrate equivalent to 50 mcg fentanyl base in Water for Injection. Sodium hydroxide and/or hydro acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5 Contains no preservative

CLINICAL PHARMACOLOGY 12

- 12.1 Mechanism of Action
- Fentanyl Citrate Injection is an opioid agonist, whose principal actions of therapeutic value are analgesia and sedation. 12.2 Pharmacodynamics

Effects on the Central Nervous System Fentanyl produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to

both increases in carbon dioxide tension and electrical stimulation Fentanyl causes miosis even in total darkness. Pinnoint nunils are a sign of opioid overdose but are not pathognomic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Effects on the Gastrointestinal Tract and Other Smooth Muscle Fentanyl causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm. esulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase

Effects on the Cardiovascular System

Fentanyl produces peripheral vasodilation which may result in ortho-static hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Effects on the Endocrine System Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.

Chronic use of opioids may influence the hypothalamic-pituitary gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see Adverse Reactions (6)].

Effects on the Immune System Opioids have been shown to have a variety of effects on components of the immune system in *in vitro* and animal models. The clinical significance of these findings is unknown. Overall, the effects of pioids appear to be modestly immunosuppressive.

Concentration - Efficacy Relationships

A dose of 100 mcg of Fentanyl Citrate Injection is approximate equivalent in analgesic activity to 10 mg of morphine or 75 mg of meneridine

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. The minimum effective analgesic concentration of fentanyl for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance /see Dosage and Administration (2.1)

The onset of action of fentanyl is almost immediate when the drug is given intravenously; however, the maximal analgesic effect may not be noted for several minutes. The usual duration of action of the analgesic effect is 30 to 60 minutes after a single intravenous dose of up to 100 mcg. Following intramuscular administration, the onset of action is from seven to eight minutes, and the duration of action is one to two hours.

Concentration - Adverse Reaction Relationships

here is a relationship between increasing fentanyl plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory lepression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions see Dosage and Administration (2.1).

The onset of action of fentanyl is almost immediate when the drug is given intravenously; however, the maximal respiratory depressant effect may not be noted for several minutes. As with longer acting narcotic analgesics, the duration of the respiratory depressant effect of fentanyl may be longer than the analgesic effect. The following observations have been reported concerning altered respiratory response to CO₂ stimulation following administration of fentanyl citrate:
 Diminished sensitivity to CO₂ stimulation may persist longe

than depression of respiratory rate. (Altered sensitivity to CO₂ stimulation has been demonstrated for up to four hours following a single-dose of 600 mcg fentanyl to healthy volunteers.) Fentany requently slows the respiratory rate, duration and degree of espiratory depression being dose related

• The peak respiratory depressant effect of a single intravenous dose of fentanyl citrate is noted 5 to 15 minutes following injection [see Warnings and Precautions (5.2)]

12.3 Pharmacokinetics

Fentanyl Citrate Injection is administered by the intravenous or intramuscular route. The pharmacokinetics of fentanyl can be described as a three-compartment model.

Fentanyl plasma protein binding capacity increases with increasing ionization of the drug. Alterations in pH may affect its distribution between plasma and the central nervous system. It accumulates in skeletal muscle and fat and is released slowly into the blood. The volume of distribution for fentanyl is 4 L/kg. It has a distribution time of 1.7 minutes and redistribution time of 13 minutes.

Elimination The terminal elimination half-life is 219 minutes.

Fentanyl, which is primarily transformed in the liver, demonstrates a high first pass clearance and releases approximately 75% of an intravenous dose in urine, mostly as metabolites with less than 10% representing the unchanged drug. Approximately 9% of the dose is recovered in the feces, primarily as metabolites

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u> Long-term studies in animals to evaluate the carcinogenic potential of fentanyl citrate have not been conducted Mutagenesis

No formal studies to assess the mutagenic potential of fentanyl citrate have been conducted

Impairment of Fertility

ed pregnancy rates occurred in a multigenerational study in which pregnant rats were treated subcutaneously during the first 21 days of pregnancy with 160 mcg/kg to 1250 mcg/kg fentanyl (0.26 times to 2.0 times a human dose of 100 mcg/kg based on body surface area).

Studies in animals to characterize the effect of fentanyl on male fertility have not been conducted

HOW SUPPLIED/STORAGE AND HANDLING Fentanyl Citrate Injection is supplied as a sterile, clear, and colorless

Fentanyl Citrate Injection, equivalent to 50 mcg fentanyl base per mL, is a preservative-free solution, supplied as follows:

Product Code	Unit of Sale	Strength	Each
806101	NDC 63323-806-01 Unit of 25	50 mcg in 1 mL (50 mcg per mL)	NDC 63323-806-11 1 mL fill in a 2 mL single-dose vial
806102	NDC 63323-806-02	100 mcg in 2 mL	NDC 63323-806-12
	Unit of 25	(50 mcg per mL)	2 mL single-dose vi
806105	NDC 63323-806-05	250 mcg in 5 mL	NDC 63323-806-13
	Unit of 25	(50 mcg per mL)	5 mL single-dose vi

For Intravenous Use by Hospital Personnel Specifically Trained in the

	000	of Maroono / margoon		
	Product Code	Unit of Sale	Strength	Each
	806120	NDC 63323-806-20 Unit of 25	1,000 mcg in 20 mL (50 mcg per mL)	NDC 63323-806-14 20 mL single-dose v
	806150	NDC 63323-806-50	2,500 mcg in 50 mL (50 mcg per mL)	NDC 63323-806-50 50 mL single-dose v packaged individual

PROTECT FROM LIGHT. Keep covered in carton until time of use. Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Contains no preservative. DISCARD ANY UNUSED CONTENTS.

The container closure is not made with natural rubber latex. Parenteral drug products should be inspected visually for particulate natter and discoloration prior to administration, whenever solution and container permit

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

17 PATIENT COUNSELING INFORMATION

Serotonin Syndrome Inform patients that Fentanyl Citrate Injection could cause a rare but potentially life-threatening condition resulting from concomitan histration of serotonergic drugs. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions (5.7), Drug Interactions

dvise patients of the potential for severe constipation, [see Clinical Pharmacology (12.2)]



For Product Inquiry: -800-551-7176 or www.fresenius-kabi.com/us